Long‐term efficacy and safety results of taliglucerase alfa up to 36 months in adult treatment‐naïve patients with Gaucher disease

Taliglucerase alfa is an intravenous enzyme replacement therapy approved for treatment of type 1 Gaucher disease (GD), and is the first available plant cell–expressed recombinant therapeutic protein. Herein, we report long‐term safety and efficacy results of taliglucerase alfa in treatment‐naïve adu...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Am J Hematol
Autori principali: Zimran, Ari, Durán, Gloria, Mehta, Atul, Giraldo, Pilar, Rosenbaum, Hanna, Giona, Fiorina, Amato, Dominick J., Petakov, Milan, Muñoz, Eduardo Terreros, Solorio‐Meza, Sergio Eduardo, Cooper, Peter A., Varughese, Sheeba, Chertkoff, Raul, Brill‐Almon, Einat
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2016
Soggetti:
Original Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5074246/
https://ncbi.nlm.nih.gov/pubmed/27174694
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.24369
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi